Obesity and its comorbidities, such as type 2 diabetes, are major public health diseases in modern society. Despite the currently significant unmet needs of type 2 diabetes patients, effective and safe pharmacological treatments that deliver adequate weight loss and glucose control have not been discovered.
Anti-obesity Anti-diabetes gon and GLP-1 synergistically increases resting energy expenditure and insulin level. 16 In both preclinical and clinical studies, the combination of GLP-1 and glucagon showed anti-diabetic and anti-obesity synergistic effects.
Unimolecular GLP-1/GIP/glucagon triagonist
Due to recently developed high-technology approaches, research focusing on unimolecular co-agonists is currently being conducted. In particular, the 3 hormones, GLP-1, GIP and glucagon, have unique enteroinsular effects as well as roles in the regulation of energy and glucose homeostasis. Several studies reported the unimolecular, balanced, GLP-1/GIP/glucagon triagonist is superior to the respective dual agonists. 17, 18 At a low dose, liraglutide and the GIP/glucagon co-agonist did not improve body weight, whereas triagonist decreased body weight by 15.1%.
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The co-agonist and the triagonist were both equally effective in improving glucose tolerance and decreasing ad libitum-fed blood glucose without hypoglycemia. However, the triagonist decreased the plasma concentrations of insulin more than the coagonists, indicating insulin sensitivity improved more with a triagonist than with a co-agonist. Furthermore, the triagonist lowered the circulating concentration of cholesterol thus lowering hepatic lipid content and hepatocellular vacuolation. Enhanced energy expenditure was also observed in triagonist-treated DIO mice compared with pair-fed controls. In another study, GLP-1/ GIP/glucagon triagonist decreased body weight, exerted insulin secretory actions and improved both glucose tolerance and insulin resistance in mice fed a high-fat diet. 18 Collectively, these preclinical studies showed the triagonist of incretin components has anti-obesity and anti-diabetes potential.
GLP-1 and PYY
PYY is secreted with GLP-1 in the L cells of the distal gut after nutrient ingestion to reduce appetite and food intake. GLP-1 and PYY bind to GLP-1R and neuropeptide Y2-receptor, respectively. 19, 20 Both receptors are found in the arcuate nucleus of the hypothalamus, dorsal vagal complex, nucleus tractus solitarii, area postrema and nodose ganglion of the vagus nerve. 21, 22 When PYY and GLP-1 were administered together intravenously to fasted humans, energy intake was reduced and activity in several areas of the brain involved in response to satiety increased. 23 Co-administration of both peptides to humans induced pre-meal insulin secretion. 24 Preclinical studies in mice showed that systemic co-administration of PYY and Exendin-4, a long acting GLP-1, synergistically decreased appetite and food intake independent of the GLP-1R signaling pathway. 25 In clinical and preclinical studies, the combination of GLP-1 and PYY demonstrated anti-obesity effects.
GLP-1 and other combinations
Several other combinations, including leptin, calcitonin, naltrexone, cholecystokinin (CCK) or gastrin with GLP-1, have been investigated for anti-obesity and anti-diabetic effects. CCK is a typical gastrointestinal hormone that promotes satiety after eating. When CCK is infused with GLP-1 to healthy humans, hunger feelings were synergistically reduced before meals. 26 Leptin is an anorectic hormone secreted by WAT by binding to the leptin receptor. Intraperitoneal co-administration of GLP-1 and leptin significantly reduced food intake in rats by transmitting the anorectic signal via the ascending neural pathway from the hindbrain. 27 The combination of Exendin-4 and leptin showed an additive effect on food intake reduction. 28 Naltrexone is an opioid antagonist acting on the reward system. The combination of naltrexone and Exendin-4 synergistically suppressed food intake in a dose-dependent manner and resulted in a rapid acquisition of a conditioned taste aversion. 29 Amylin is a pancreatic peptide co-secreted with insulin and involved in the control of satiety signaling. The combination of Exendin-4 and an amylin analog, salmon calcitonin, elicited a synergistic effect on reducing food intake and produced body weight loss in monkeys. 
CONCLUSION
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